Канал: The Society for Translational Oncology

Perspectives from a Multidisciplinary Oncology Team on How to Reduce Racial Disparities

Perspectives from a Multidisciplinary Oncology Team on How to Reduce Racial Disparities

Part 5 - Molecular and Precision Medicine (MAP) Series

Part 5 - Molecular and Precision Medicine (MAP) Series

Part 3 - Molecular and Precision Medicine (MAP) Series

Part 3 - Molecular and Precision Medicine (MAP) Series

Part 2 - Molecular and Precision Medicine (MAP) Series

Part 2 - Molecular and Precision Medicine (MAP) Series

Part 1 - Molecular and Precision Medicine (MAP) Series

Part 1 - Molecular and Precision Medicine (MAP) Series

Part 4 - Molecular and Precision Medicine (MAP) Series

Part 4 - Molecular and Precision Medicine (MAP) Series

Preferentially Targeting the Malignant Hematopoietic Clone in Myeloproliferative Neoplasms (MPN)

Preferentially Targeting the Malignant Hematopoietic Clone in Myeloproliferative Neoplasms (MPN)

Integrating Pathologic and Genomic Factors to Make Treatment Decisions in Patients with GI Cancers

Integrating Pathologic and Genomic Factors to Make Treatment Decisions in Patients with GI Cancers

Targeting SWI/SNF-Hippo Axis in Squamous Cancers

Targeting SWI/SNF-Hippo Axis in Squamous Cancers

IDH Inhibition in Acute Myeloid Leukemia –Emergence of a New Therapeutic Era

IDH Inhibition in Acute Myeloid Leukemia –Emergence of a New Therapeutic Era

Epigenetic Reversal of Chemotherapy Resistance in Cancers

Epigenetic Reversal of Chemotherapy Resistance in Cancers

Cross-resistance in Small Cell Lung Cancer

Cross-resistance in Small Cell Lung Cancer

RET As a Target in Lung Cancer

RET As a Target in Lung Cancer

Innovations in Cell Therapy

Innovations in Cell Therapy

ctDNA, a Biomarker of Residual Disease and Tumor Response in Gastrointestinal Cancers

ctDNA, a Biomarker of Residual Disease and Tumor Response in Gastrointestinal Cancers

(Overview) Targeting Cell Death Pathways with Precision Using Functional Assays

(Overview) Targeting Cell Death Pathways with Precision Using Functional Assays

(Overview) Molecular Tumor Board: Resistance to Checkpoint Inhibitors Part 2

(Overview) Molecular Tumor Board: Resistance to Checkpoint Inhibitors Part 2

(Overview) CAR-T Cell Therapy of Ovarian Cancer

(Overview) CAR-T Cell Therapy of Ovarian Cancer

(Overview) Microfluidics for the Characterization of Tumor-specific Extracellular Vesicles

(Overview) Microfluidics for the Characterization of Tumor-specific Extracellular Vesicles

(Overview) Beyond PARP1: Ribosylation as a Target for Cancer Therapy

(Overview) Beyond PARP1: Ribosylation as a Target for Cancer Therapy

(Overview) New Biomarkers in a Novel Antibody-drug Conjugate for Triple Negative Breast Cancer

(Overview) New Biomarkers in a Novel Antibody-drug Conjugate for Triple Negative Breast Cancer

(Overview) Molecular Tumor Board: Resistance to Checkpoint Inhibitors - Part 1

(Overview) Molecular Tumor Board: Resistance to Checkpoint Inhibitors - Part 1

(Overview) Lin28B, a Promoter of Metastasis and Drug Resistance

(Overview) Lin28B, a Promoter of Metastasis and Drug Resistance

(Overview) Clinical Application of Liquid Biopsies and Genotype directed Targeted...

(Overview) Clinical Application of Liquid Biopsies and Genotype directed Targeted...

(Overview) Melanoma: Clues to Improved Therapeutic Efficacy from Disease Pathogenesis

(Overview) Melanoma: Clues to Improved Therapeutic Efficacy from Disease Pathogenesis

(Overview) Clinical Utility of Longitudinal Molecular Profiling for Management of ALK-Positive...

(Overview) Clinical Utility of Longitudinal Molecular Profiling for Management of ALK-Positive...

Developing Therapies for Ras-driven Cancers

Developing Therapies for Ras-driven Cancers

Is FGFR Inhibition an Effective Target in Gastrointestinal Tumors?

Is FGFR Inhibition an Effective Target in Gastrointestinal Tumors?

PARP Inhibitor Resistance and Acquired Vulnerability in Ovarian Cancer

PARP Inhibitor Resistance and Acquired Vulnerability in Ovarian Cancer

Genomic and Functional Characterization of Patient Derived Xenograft Models of SCLC

Genomic and Functional Characterization of Patient Derived Xenograft Models of SCLC

PARP in Breast Cancer

PARP in Breast Cancer

Antibody Drug Conjugates for Triple Negative Breast Cancer: Targeting Positive in the Negative

Antibody Drug Conjugates for Triple Negative Breast Cancer: Targeting Positive in the Negative

Assessing DNA Repair in Clinical Trials

Assessing DNA Repair in Clinical Trials

Intergenic Fusions in Advanced HR+ Breast Cancer

Intergenic Fusions in Advanced HR+ Breast Cancer

Targeting the ATR Kinase in Cancer Therapy

Targeting the ATR Kinase in Cancer Therapy

Molecular Tumor Board

Molecular Tumor Board

Epigenetic Mechanisms of Tumor Initiation and Evolution

Epigenetic Mechanisms of Tumor Initiation and Evolution

Addressing Cancer Clonal Heterogeneity: Developing Personalized Neoantigen-Based Cancer Vaccines

Addressing Cancer Clonal Heterogeneity: Developing Personalized Neoantigen-Based Cancer Vaccines

Genomics of a Mitochondria-Rich Tumor

Genomics of a Mitochondria-Rich Tumor

Developing Therapies for Transcriptionally Addicted Tumors

Developing Therapies for Transcriptionally Addicted Tumors

Dihydroorotate Dehydrogenase: An Unexpected Metabolic Vulnerability in Acute Myeloid Leukemia

Dihydroorotate Dehydrogenase: An Unexpected Metabolic Vulnerability in Acute Myeloid Leukemia

Generation of Models of Human Hematologic Malignancies Using CRISPR Genome Engineering

Generation of Models of Human Hematologic Malignancies Using CRISPR Genome Engineering

Optimal MAPK Inhibition as a Key Component of Therapeutic Strategies for KRAS Mutant Cancers

Optimal MAPK Inhibition as a Key Component of Therapeutic Strategies for KRAS Mutant Cancers

T-Cell Therapy: Current Applications and Future Directions

T-Cell Therapy: Current Applications and Future Directions

FLT3 Inhibitors in the Therapy of Acute Myeloid Leukemia

FLT3 Inhibitors in the Therapy of Acute Myeloid Leukemia

Molecular Analysis of CTCs in Prostate Cancer

Molecular Analysis of CTCs in Prostate Cancer

Oncology Drug Development in the Era of Precision Medicine: FDA Perspective

Oncology Drug Development in the Era of Precision Medicine: FDA Perspective

The Changing Nature of Phase I Trials

The Changing Nature of Phase I Trials

Emerging Therapies to Optimize MAP Kinase Blockade and Intercept Compensatory Signaling

Emerging Therapies to Optimize MAP Kinase Blockade and Intercept Compensatory Signaling

Monitoring Cancer Through Circulating Tumor Cells

Monitoring Cancer Through Circulating Tumor Cells

The Lazarex-MGH Cancer Care Equity Program

The Lazarex-MGH Cancer Care Equity Program

The “BRCA-Like” Phenotype in Cancer

The “BRCA-Like” Phenotype in Cancer

Loss of SIRT6 Reactivates the Oncofetal Protein Lin28b to Drive Pancreatic Cancer

Loss of SIRT6 Reactivates the Oncofetal Protein Lin28b to Drive Pancreatic Cancer

Alternative Lengthening of Telomeres Renders Cancer Cells Hypersensitive to ATR Inhibitors

Alternative Lengthening of Telomeres Renders Cancer Cells Hypersensitive to ATR Inhibitors

Pathogenesis and Therapy of IDH-TET-Mutant Myeloid Malignancies

Pathogenesis and Therapy of IDH-TET-Mutant Myeloid Malignancies

The Histone Deacetylase SIRT6: Linking Epigenetics to Cancer Metabolism

The Histone Deacetylase SIRT6: Linking Epigenetics to Cancer Metabolism

Lessons From the Study of Extraordinary Responders Solit

Lessons From the Study of Extraordinary Responders Solit

EZH2 Inhibition in SWI/SNF Altered Sarcomas

EZH2 Inhibition in SWI/SNF Altered Sarcomas

Late Breaking Advances RNF43 Mutations in Colon Cancer Marios Giannakis

Late Breaking Advances RNF43 Mutations in Colon Cancer Marios Giannakis

Understanding Myelodysplastic Syndromes (MDS)

Understanding Myelodysplastic Syndromes (MDS)

Curative Potential of Cell Transfer Immunotherapy for Cancer

Curative Potential of Cell Transfer Immunotherapy for Cancer

Molecular Interrogation of Circulating Tumor Cells for Drug Development in Breast Cancer

Molecular Interrogation of Circulating Tumor Cells for Drug Development in Breast Cancer

Advances in Molecular Screening NGS

Advances in Molecular Screening NGS

Exploiting Methylthioadenosine Phosphorylase Deficiency in Cancer

Exploiting Methylthioadenosine Phosphorylase Deficiency in Cancer

Improving the Treatment of Prostate Cancer

Improving the Treatment of Prostate Cancer

Molecular Profile of Acute Myeloid Leukemia (AML)

Protein Methyltransferase Inhibitors as Personalized Cancer Therapeutics

Protein Methyltransferase Inhibitors as Personalized Cancer Therapeutics

The Stem Cell Regulator Lin28 in Malignancy

The Stem Cell Regulator Lin28 in Malignancy

Targeting Cancer Stem Cells for Durable Response

Targeting Cancer Stem Cells for Durable Response

Next Steps in Melanoma Treatment

Next Steps in Melanoma Treatment

Molecular Analysis of CTCs

Molecular Analysis of CTCs

Leveraging Genetically Engineered Mouse Models of SCLC for Advanced Therapeutic Studies

Leveraging Genetically Engineered Mouse Models of SCLC for Advanced Therapeutic Studies

EGFR Mutant Lung Cancer: 2013 Update

EGFR Mutant Lung Cancer: 2013 Update

Histone H3K27 Demethylases as a Therapeutic Target in Polysomy 21 Leukemia

Histone H3K27 Demethylases as a Therapeutic Target in Polysomy 21 Leukemia

ALK and ROS1 in Lung Cancer Next Generation Targeted Therapies

ALK and ROS1 in Lung Cancer Next Generation Targeted Therapies

"Click" Chemistry In Vivo - New Tools for Molecular Imaging

"Click" Chemistry In Vivo - New Tools for Molecular Imaging

TERT Promoter Mutations in Cancer

TERT Promoter Mutations in Cancer

Multiple Roles of MITF in Melanoma and Melanocycle Biology

Multiple Roles of MITF in Melanoma and Melanocycle Biology

Bacterial Genomics in Transplant-related Colitis

Bacterial Genomics in Transplant-related Colitis

Chromatin Modulators Provide a New Insight into Cancer Genomes

Chromatin Modulators Provide a New Insight into Cancer Genomes

Colon Cancer 2013 Why it's hard to develop drugs - by David P. Ryan, MD

Colon Cancer 2013 Why it's hard to develop drugs - by David P. Ryan, MD

Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhD

Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhD

Advances in Targeted Therapies for Lung Cancer - by Alice T. Shaw, MD PhD

Advances in Targeted Therapies for Lung Cancer - by Alice T. Shaw, MD PhD

Prospects for Targeted Therapy in Ovarian Cancer - by Michael Birrer, MD, PhD

Prospects for Targeted Therapy in Ovarian Cancer - by Michael Birrer, MD, PhD

Role of VEGFR and MET in Prostate Cancer -by Matthew Smith, MD, PhD

Role of VEGFR and MET in Prostate Cancer -by Matthew Smith, MD, PhD

Smart T Cell Vaccines: CAR T Cells - by Carl June, MD

Smart T Cell Vaccines: CAR T Cells - by Carl June, MD

Mutation Based Resistance to TKI Therapy - by Frank G. Haluska, MD, PhD

Mutation Based Resistance to TKI Therapy - by Frank G. Haluska, MD, PhD

Targeting the PI3K Pathway in the Therapy of Breast Cancer - by Jose Baselga, MD, PhD

Targeting the PI3K Pathway in the Therapy of Breast Cancer - by Jose Baselga, MD, PhD

Systematic Identification of Genomic Markers of Drug Sensitivity in Cancer Cells

Systematic Identification of Genomic Markers of Drug Sensitivity in Cancer Cells

Advanced Bladder Cancer: Moving the Field Forward - by Matthew I. Milowsky, MD

Advanced Bladder Cancer: Moving the Field Forward - by Matthew I. Milowsky, MD

Molecular Markers for Guiding Colorectal Cancer Therapy - by Bert O'Neil, MD

Molecular Markers for Guiding Colorectal Cancer Therapy - by Bert O'Neil, MD

Molecular Tests for Targeted Therapies in Advanced NSCLC - by Thomas E. Stinchcombe, MD

Molecular Tests for Targeted Therapies in Advanced NSCLC - by Thomas E. Stinchcombe, MD

Imaging Approaches in Oncology: Update on PET/CT - by Terence Z. Wong, MD, PhD

Imaging Approaches in Oncology: Update on PET/CT - by Terence Z. Wong, MD, PhD

Exosomes as Biomarkers for Brain Tumors - by Xandra O. Breakefield, PhD

Exosomes as Biomarkers for Brain Tumors - by Xandra O. Breakefield, PhD

Publicly Funded Clinical Trials and Cancer Care - by Richard L. Schilsky, MD

Publicly Funded Clinical Trials and Cancer Care - by Richard L. Schilsky, MD

Prognostication in Breast Cancer: Are We Smarter Yet? - by Lisa A. Carey, MD

Prognostication in Breast Cancer: Are We Smarter Yet? - by Lisa A. Carey, MD

STO Annual Meeting 2012: Welcome and Introduction

STO Annual Meeting 2012: Welcome and Introduction

Awarding of the 2012 Pinedo Cancer Care Prize - by Martin J. Murphy, DMedSc, PhD

Awarding of the 2012 Pinedo Cancer Care Prize - by Martin J. Murphy, DMedSc, PhD

Pulverizing Metastatic Melanoma - by Stergios J. Moschos, MD

Pulverizing Metastatic Melanoma - by Stergios J. Moschos, MD

Improving Overall Survival after Stem Cell Transplant - by Stefanie Sarantopoulos, MD, PhD

Improving Overall Survival after Stem Cell Transplant - by Stefanie Sarantopoulos, MD, PhD

Genome and Clinic in the Care of Renal Cell Carcinoma - by W. Kimryn Rathmell, MD, PhD

Genome and Clinic in the Care of Renal Cell Carcinoma - by W. Kimryn Rathmell, MD, PhD

Nanotechnology-enabled High Resolution DBT - by Otto Zhou, PhD

Nanotechnology-enabled High Resolution DBT - by Otto Zhou, PhD

PET/MR: Useful Instrument or Just Looking for Nails? - by Yueh "Ray" Lee, MD

PET/MR: Useful Instrument or Just Looking for Nails? - by Yueh "Ray" Lee, MD

Case Presentation: Pulmonary Metastasectomy - by Benjamin Haithcock, MD

Case Presentation: Pulmonary Metastasectomy - by Benjamin Haithcock, MD

MRI in Oncology - 2012 - by W. Brian Hyslop, MD, PhD

MRI in Oncology - 2012 - by W. Brian Hyslop, MD, PhD

Better Proteasome Inhibitor-Based Therapy in MM - by Pete Voorhees, MD

Better Proteasome Inhibitor-Based Therapy in MM - by Pete Voorhees, MD

Case Presentation: Treating Brain Metastases - by Matthew Ewend, MD

Case Presentation: Treating Brain Metastases - by Matthew Ewend, MD

Screening for Colon Cancer - by Richard M. Goldberg, MD

Screening for Colon Cancer - by Richard M. Goldberg, MD

Redefining Cancer Drug Development - Interview with Dr. William Hait

Redefining Cancer Drug Development - Interview with Dr. William Hait

Case Presentation: Oligometastases - by Hong Jin Kim, MD

Case Presentation: Oligometastases - by Hong Jin Kim, MD

Lung Cancer Screening - by Nirmal Veeramachaneni, MD

Lung Cancer Screening - by Nirmal Veeramachaneni, MD

Radiosurgical Approaches for Oligometastatic Disease - by Joel Tepper, MD

Radiosurgical Approaches for Oligometastatic Disease - by Joel Tepper, MD

The Impact of Genomic and Signaling Research on Clinical Research - by H. Shelton Earp, MD

The Impact of Genomic and Signaling Research on Clinical Research - by H. Shelton Earp, MD

Image-Guided Onco-Intervention - by Matthew A. Mauro, MD, FACR, FAHA, FSIR

Image-Guided Onco-Intervention - by Matthew A. Mauro, MD, FACR, FAHA, FSIR

Controlling the Cell Cycle in Cancer Therapy - by Norman E. Sharpless, MD

Controlling the Cell Cycle in Cancer Therapy - by Norman E. Sharpless, MD

PSA Screening for Prostate Cancer - by Paul Godley, MD, PhD, MPP

PSA Screening for Prostate Cancer - by Paul Godley, MD, PhD, MPP

Roundtable - Management of Anemia in Patients Receiving Chemotherapy by Chair: Mario Dicato

Roundtable - Management of Anemia in Patients Receiving Chemotherapy by Chair: Mario Dicato

IDH1 and Other Targets in Metabolism by Matthew Vander Heiden, MD, PhD

IDH1 and Other Targets in Metabolism by Matthew Vander Heiden, MD, PhD

MUC-1, Biology and Target for Therapy by Donald Kufe, MD

MUC-1, Biology and Target for Therapy by Donald Kufe, MD

Resistance in Colorectal Cancer by Ryan B. Corcoran, MD, PhD

Resistance in Colorectal Cancer by Ryan B. Corcoran, MD, PhD

SCLC The Next Frontier in Lung Cancer Therapy by Leena Gandhi, MD, PhD

SCLC The Next Frontier in Lung Cancer Therapy by Leena Gandhi, MD, PhD

Satellite RNA as a Biomarker by Bradley Bernstein, MD, PhD

Satellite RNA as a Biomarker by Bradley Bernstein, MD, PhD

Stem Cells and Cancer by David Scadden, MD

Stem Cells and Cancer by David Scadden, MD

Systematic Studies of the Histone Methyl 'ome' by Bradley Bernstein, MD, PhD

Systematic Studies of the Histone Methyl 'ome' by Bradley Bernstein, MD, PhD

Targeting Activated ERK Signaling in Human Tumors Sensitivity and Resistance by Bradley Bernstein

Targeting Activated ERK Signaling in Human Tumors Sensitivity and Resistance by Bradley Bernstein

Targeting of NSCLC in 2011 by Alice Shaw, MD, PhD

Targeting of NSCLC in 2011 by Alice Shaw, MD, PhD

Targeting the PI3K pathway in Breast Cancer by Jose Baselga, MD, PhD

Targeting the PI3K pathway in Breast Cancer by Jose Baselga, MD, PhD

Dot 1L a Viable Target for Leukemia Therapy by Scott Armstrong, MD, PhD

Dot 1L a Viable Target for Leukemia Therapy by Scott Armstrong, MD, PhD

Drug Combination in Melanoma is More Better by Keith Flaherty, MD

Drug Combination in Melanoma is More Better by Keith Flaherty, MD

ErbB3 in Ovarian Cancer by Dr. Liu

ErbB3 in Ovarian Cancer by Dr. Liu

Bridging Cell Cycle and Organismal Behavior Through Histone Demethylation by J Whetstine

Bridging Cell Cycle and Organismal Behavior Through Histone Demethylation by J Whetstine

Zebrafish screens for new melanoma targets - Richard White, MD, PhD,

Zebrafish screens for new melanoma targets - Richard White, MD, PhD,

Roundtable Management of anemia in nephrology patients

Roundtable Management of anemia in nephrology patients

Update on recent ESA and blood transfusion studies

Update on recent ESA and blood transfusion studies

The Oncologist App

The Oncologist App

Personalized Therapy for Advanced NSCLC - Roy S Herbst, MD, PhD

Personalized Therapy for Advanced NSCLC - Roy S Herbst, MD, PhD

Pancreatic Cancer Medicine - Dave Tuveson, MD, PhD

Pancreatic Cancer Medicine - Dave Tuveson, MD, PhD

2011 Bob Pinedo Cancer Care Prize Award

2011 Bob Pinedo Cancer Care Prize Award

Prostate Cancer: Tumour Biology - David Waugh, PhD

Prostate Cancer: Tumour Biology - David Waugh, PhD

Prostate Cancer: Radiation Therapy - Dr. Joe O'Sullivan, Bruce A. Chabner, MD

Prostate Cancer: Radiation Therapy - Dr. Joe O'Sullivan, Bruce A. Chabner, MD

Prostate Cancer: New Systemic Treatments - Johann Sebastian de Bono, MB ChB FRCP MSc PhD

Prostate Cancer: New Systemic Treatments - Johann Sebastian de Bono, MB ChB FRCP MSc PhD

Prostate Cancer: Progress and Promise - Part 2 Roundtable

Prostate Cancer: Progress and Promise - Part 2 Roundtable

Pinedo Prize: Individualized Breast Cancer Therapy

Pinedo Prize: Individualized Breast Cancer Therapy

Bone Targeted Therapies - Matthew Smith, MD, PhD

Bone Targeted Therapies - Matthew Smith, MD, PhD

Taxanes: Pivotal Agents in the Management of Metastatic Castrate-Resistant Prostate Cancer

Taxanes: Pivotal Agents in the Management of Metastatic Castrate-Resistant Prostate Cancer

Refining Early Detection and Predicting Outcomes of Primary Treatment - Martin Sanda, MD

Refining Early Detection and Predicting Outcomes of Primary Treatment - Martin Sanda, MD

Androgen Receptor Antagonists - Dana Rathkopf, MD

Androgen Receptor Antagonists - Dana Rathkopf, MD

Exploring the Complexities of Androgen Signaling in Prostate Cancer Progression - Eleni Efstathiou

Exploring the Complexities of Androgen Signaling in Prostate Cancer Progression - Eleni Efstathiou

Is Prostate Cancer Responsive to the Immune System? - Charles Drake, MD, PhD

Is Prostate Cancer Responsive to the Immune System? - Charles Drake, MD, PhD

New Prognostic Biomarkers - Ronald DePinho, MD

New Prognostic Biomarkers - Ronald DePinho, MD

Roundtable: The Growing Complexity of Treatment Choices and Strategies

Roundtable: The Growing Complexity of Treatment Choices and Strategies

STEM CELLS Translational Medicine Round Table

STEM CELLS Translational Medicine Round Table

The Oncologist Journal - Critical information. Respected source. On-demand.

The Oncologist Journal - Critical information. Respected source. On-demand.

Update on the role of blood transfusions - Axel Hofmann, ME and Aryeh Shander, MD

Update on the role of blood transfusions - Axel Hofmann, ME and Aryeh Shander, MD

Overview of the use of blood transfusions in different clinical settings

Overview of the use of blood transfusions in different clinical settings

Webcast - Expert Forum on Blood Transfusion and ESA Use

Webcast - Expert Forum on Blood Transfusion and ESA Use

Plenary discussion

Plenary discussion

ESAs in nephrology -- Aspects of the current debate - Kai-Uwe Eckardt, MD

ESAs in nephrology -- Aspects of the current debate - Kai-Uwe Eckardt, MD

The use of ESAs with and without Iron - Anders Österborg, MD

The use of ESAs with and without Iron - Anders Österborg, MD

Update on biology of erythropoeitin receptors - Joachim Fandrey, MD

Update on biology of erythropoeitin receptors - Joachim Fandrey, MD

Update on ESA studies in oncology - Mario Dicato, MD

Update on ESA studies in oncology - Mario Dicato, MD

Aromatase Inhibitors & Breast Cancer Therapy - Milestones in Oncology

Aromatase Inhibitors & Breast Cancer Therapy - Milestones in Oncology

Targeted Therapies for Breast Cancer - Milestones in Oncology

Targeted Therapies for Breast Cancer - Milestones in Oncology

Breast Cancer: New Treatments & Improved Therapies - Milestones in Oncology

Breast Cancer: New Treatments & Improved Therapies - Milestones in Oncology

Lung Cancer at the Advent of Targeted Therapy - Milestones in Oncology

Lung Cancer at the Advent of Targeted Therapy - Milestones in Oncology

Molecular Stratification of Triple Negative Breast Cancers

Molecular Stratification of Triple Negative Breast Cancers

Coming of Age: Breast Cancer in Seniors

Coming of Age: Breast Cancer in Seniors

The Biological Framework: Translational Research from Bench to Clinic - Yosef Yarden, PhD

The Biological Framework: Translational Research from Bench to Clinic - Yosef Yarden, PhD

Neuroblastoma Immunotherapy by Paul M. Sondel, MD, PhD

Neuroblastoma Immunotherapy by Paul M. Sondel, MD, PhD

The Clinical Framework: Towards an Individual Approach

The Clinical Framework: Towards an Individual Approach

Zebrafish as a Model for Human Cancer by Leonard Zon, MD

Zebrafish as a Model for Human Cancer by Leonard Zon, MD

Targeting the Phosphoinositide-3 Kinase (PI3K) Pathway in Breast Cancer - José Baselga, MD

Targeting the Phosphoinositide-3 Kinase (PI3K) Pathway in Breast Cancer - José Baselga, MD

New Perspectives in Chemotherapy - Dr. Sandra Swain

New Perspectives in Chemotherapy - Dr. Sandra Swain

Hormone Receptor Positive Disease: New Developments - Martine J. Piccart-Gebhart, M.D., Ph.D.

Hormone Receptor Positive Disease: New Developments - Martine J. Piccart-Gebhart, M.D., Ph.D.

Node-Negative Breast Cancer: A New Look

Node-Negative Breast Cancer: A New Look

Targeting critical oncogenic pathways in cancer - emerging molecules and translational strategies

Targeting critical oncogenic pathways in cancer - emerging molecules and translational strategies

Targeting Triple Negative Breast Cancer

Targeting Triple Negative Breast Cancer

The ALK story, a new kind of phase 1 trial

The ALK story, a new kind of phase 1 trial

Biomarker-driven drug development: from dream to reality - Mace Rothenberg, MD

Biomarker-driven drug development: from dream to reality - Mace Rothenberg, MD

Finding biomarkers: molecular profiling and CTCs - Daniel Haber, MD, MS, PhD'

Finding biomarkers: molecular profiling and CTCs - Daniel Haber, MD, MS, PhD'

The use of emerging genomic technologies to predict tumor response and drug resistance

The use of emerging genomic technologies to predict tumor response and drug resistance

BRAF: the first prevalent oncogene target to show single-agent responsiveness

BRAF: the first prevalent oncogene target to show single-agent responsiveness

DNA Repair Enzymes as Therapeutic Targets in Breast Cancer - Joyce O'Shaughnessy, MD

DNA Repair Enzymes as Therapeutic Targets in Breast Cancer - Joyce O'Shaughnessy, MD

The PI3K pathway - Lewis Cantley, PhD

The PI3K pathway - Lewis Cantley, PhD

A Coding-Independent Function of Gene and Pseudogene mRNAs Regulates Tumor Biology

A Coding-Independent Function of Gene and Pseudogene mRNAs Regulates Tumor Biology

ERBB3 - David Livingston, MD

ERBB3 - David Livingston, MD

2010 Bob Pinedo Cancer Care Prize Award - Dr. Jose Baselga

2010 Bob Pinedo Cancer Care Prize Award - Dr. Jose Baselga

Drug Discovery for Rare Diseases: The ACCRF Model - Jeff Kaufman

Drug Discovery for Rare Diseases: The ACCRF Model - Jeff Kaufman

Protein Methyl Transferases as a Novel Target Class for Molecularly Targeted Cancer Therapy

Protein Methyl Transferases as a Novel Target Class for Molecularly Targeted Cancer Therapy

Modeling ras - Tyler Jacks, PhD

Modeling ras - Tyler Jacks, PhD

Collaboration in Cancer Drug Trials: Targets, Biomarkers, and Drugs - Martin J. Murphy, DMedSc, PhD

Collaboration in Cancer Drug Trials: Targets, Biomarkers, and Drugs - Martin J. Murphy, DMedSc, PhD

2010 Pinedo Cancer Care Prize Award and Keynote Address

2010 Pinedo Cancer Care Prize Award and Keynote Address

Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment - Kenneth C. Anderson, MD

Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment - Kenneth C. Anderson, MD

Novel Strategies for Drug Development in Cancer: An Industry Perspective - Eric H. Rubin, MD

Novel Strategies for Drug Development in Cancer: An Industry Perspective - Eric H. Rubin, MD

The use of emerging genomic technologies to predict tumor response and drug resistance

The use of emerging genomic technologies to predict tumor response and drug resistance